Skip to Main Content

Advertisement

Skip Nav Destination

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma

Blood Adv (2023) 7 (5): 768–777.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement